Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model
- PMID: 34806449
- DOI: 10.1152/ajprenal.00298.2021
Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model
Abstract
Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in the polycystin 1 (PKD1) or polycystin 2 genes, presents with progressive development of kidney cysts and eventual end-stage kidney disease with limited treatment options. Previous work has shown that metformin reduces cyst growth in rapid ADPKD mouse models via inhibition of cystic fibrosis transmembrane conductance regulator-mediated fluid secretion, mammalian target of rapamycin, and cAMP pathways. The present study importantly tested the effectiveness of metformin as a therapy for ADPKD in a more clinically relevant Pkd1RC/RC mouse model, homozygous for the R3277C knockin point mutation in the Pkd1 gene. This mutation causes ADPKD in humans. Pkd1RC/RC male and female mice, which have a slow progression to end-stage kidney disease, received metformin (300 mg/kg/day in drinking water vs. water alone) from 3 to 9 or 12 mo of age. As previously reported, Pkd1RC/RC females had a more severe disease phenotype as compared with males. Metformin treatment reduced the ratio of total kidney weight-to-body weight relative to age-matched and sex-matched untreated controls at both 9 and 12 mo and reduced the cystic index in females at 9 mo. Metformin also increased glomerular filtration rate, lowered systolic blood pressure, improved anemia, and lowered blood urea nitrogen levels relative to controls in both sexes. Moreover, metformin reduced gene expression of key inflammatory markers and both gene and protein expression of kidney injury marker-1 and cyclin-dependent kinase-1 versus untreated controls. Altogether, these findings suggest several beneficial effects of metformin in this highly relevant slowly progressive ADPKD mouse model, which may help inform new ADPKD therapies in patients.NEW & NOTEWORTHY Metformin treatment improved ADPKD disease severity in a relevant, slowly progressive ADPKD mouse model that recapitulates a PKD-associated PKD1 mutation. Relative to controls, metformin reduced kidney weight/body weight, cystic index and BUN levels, while improving GFR, blood pressure and anemia. Metformin also reduced key inflammatory and injury markers, along with cell proliferation markers. These findings suggest several beneficial effects of metformin in this ADPKD mouse model, which may help inform new ADPKD therapies in patients.
Keywords: AMP-activated protein kinase; autosomal dominant polycystic kidney disease; glomerular filtration rate; kidney; metformin.
Similar articles
-
Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease.Am J Physiol Renal Physiol. 2023 Dec 1;325(6):F857-F869. doi: 10.1152/ajprenal.00056.2023. Epub 2023 Oct 12. Am J Physiol Renal Physiol. 2023. PMID: 37823195 Free PMC article.
-
Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.Am J Physiol Renal Physiol. 2022 Mar 1;322(3):F258-F267. doi: 10.1152/ajprenal.00262.2021. Epub 2022 Jan 17. Am J Physiol Renal Physiol. 2022. PMID: 35037466 Free PMC article.
-
Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice.Hum Mol Genet. 2022 May 19;31(10):1560-1573. doi: 10.1093/hmg/ddab340. Hum Mol Genet. 2022. PMID: 34957500
-
Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans.J Nephrol. 2017 Aug;30(4):511-519. doi: 10.1007/s40620-017-0395-9. Epub 2017 Apr 7. J Nephrol. 2017. PMID: 28390001 Review.
-
Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.Minerva Med. 2017 Feb;108(1):43-56. doi: 10.23736/S0026-4806.16.04830-8. Epub 2016 Oct 4. Minerva Med. 2017. PMID: 27701376 Review.
Cited by
-
Autosomal Dominant Polycystic Kidney Disease: Is There a Role for Autophagy?Int J Mol Sci. 2023 Sep 28;24(19):14666. doi: 10.3390/ijms241914666. Int J Mol Sci. 2023. PMID: 37834113 Free PMC article. Review.
-
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease.Drugs. 2022 Jul;82(10):1095-1115. doi: 10.1007/s40265-022-01745-9. Epub 2022 Jul 19. Drugs. 2022. PMID: 35852784 Free PMC article. Review.
-
Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Front Pharmacol. 2022 May 18;13:885457. doi: 10.3389/fphar.2022.885457. eCollection 2022. Front Pharmacol. 2022. PMID: 35662736 Free PMC article.
-
Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model.Front Mol Biosci. 2023 Jan 19;10:1058825. doi: 10.3389/fmolb.2023.1058825. eCollection 2023. Front Mol Biosci. 2023. PMID: 36743216 Free PMC article.
-
Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.Trials. 2025 Aug 25;26(1):302. doi: 10.1186/s13063-025-09010-6. Trials. 2025. PMID: 40855441 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials